Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | MDK | P21741 | 3/20 | 0.43 |
| ▸ | BDNF | P23560 | 3/20 | 0.43 |
| ▸ | PTN | P21246 | 2/20 | 0.43 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15274904 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL12213976 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL15215584 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL18254178 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL12085239 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL25121361 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL15082697 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL4544701 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL21374694 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL10157433 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216575-A1 | BIOPOLYMER SCAFFOLDS AND METHODS FOR PRODUCTION OR USE THEREOF | BIONOVA MEDICAL, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230270761-A1 | IMMUNOMODULATORY, ORAL MICROBIOME ALTERING AND TISSUE REGENERATIVE ORAL CARE COMPOSITIONS AND METHODS OF USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL AND PERI-IMPLANT DISEASES | JANOSI FAIR KATALIN (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230226200-A1 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2023-07-20 | — | — | US | disclosed |
| EP-1951761-B1 | NEW DERIVATIVES OF HYALURONIC ACID, THEIR PREPARATION PROCESS AND THEIR USES | CENTRE NAT RECH SCIENT (FR) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270761-A1 | IMMUNOMODULATORY, ORAL MICROBIOME ALTERING AND TISSUE REGENERATIVE ORAL CARE COMPOSITIONS AND METHODS OF USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL AND PERI-IMPLANT DISEASES | AHCY, CD44, TIMCC | MAPK1 2827/4885LGALS3 605/4885LGALS8 2027/4885 |
| US-20230226200-A1 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | CNR2, CNR1, FAAH | MAPK1 2199/4885LGALS3 1341/4885LGALS8 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.